NN Investment Partners Holdings N.V. Acquires 484,805 Shares of Abbott Laboratories (ABT)
NN Investment Partners Holdings N.V. increased its position in Abbott Laboratories (NYSE:ABT) by 22.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,632,358 shares of the healthcare product maker’s stock after buying an additional 484,805 shares during the period. Abbott Laboratories makes up about 1.0% of NN Investment Partners Holdings N.V.’s investment portfolio, making the stock its 21st largest position. NN Investment Partners Holdings N.V.’s holdings in Abbott Laboratories were worth $101,108,000 at the end of the most recent reporting period.
Several other institutional investors also recently made changes to their positions in the company. Patten Group Inc. raised its position in shares of Abbott Laboratories by 66.0% in the third quarter. Patten Group Inc. now owns 2,516 shares of the healthcare product maker’s stock valued at $103,000 after buying an additional 1,000 shares in the last quarter. Kanaly Trust Co raised its position in shares of Abbott Laboratories by 3.7% in the third quarter. Kanaly Trust Co now owns 2,584 shares of the healthcare product maker’s stock valued at $109,000 after buying an additional 91 shares in the last quarter. Guidant Wealth Advisors acquired a new position in shares of Abbott Laboratories during the third quarter valued at $130,000. Bruderman Asset Management LLC raised its position in shares of Abbott Laboratories by 0.3% in the third quarter. Bruderman Asset Management LLC now owns 3,124 shares of the healthcare product maker’s stock valued at $132,000 after buying an additional 10 shares in the last quarter. Finally, Apriem Advisors raised its position in shares of Abbott Laboratories by 4.2% in the third quarter. Apriem Advisors now owns 3,419 shares of the healthcare product maker’s stock valued at $145,000 after buying an additional 139 shares in the last quarter. Institutional investors own 62.20% of the company’s stock.
Shares of Abbott Laboratories (NYSE:ABT) opened at 44.20 on Friday. The company has a market cap of $65.08 billion, a P/E ratio of 47.17 and a beta of 0.97. Abbott Laboratories has a 52 week low of $36.76 and a 52 week high of $45.79. The firm has a 50-day moving average of $41.31 and a 200 day moving average of $41.16.
Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Monday, February 6th. The healthcare product maker reported $0.65 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.65. The company had revenue of $5.33 billion for the quarter, compared to analyst estimates of $5.41 billion. Abbott Laboratories had a net margin of 6.71% and a return on equity of 15.74%. The firm’s revenue was up 2.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.62 EPS. Equities analysts anticipate that Abbott Laboratories will post $2.45 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Wednesday, February 15th. Investors of record on Friday, January 13th were issued a dividend of $0.265 per share. The ex-dividend date was Wednesday, January 11th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.26. This represents a $1.06 annualized dividend and a dividend yield of 2.40%. Abbott Laboratories’s payout ratio is 113.98%.
“NN Investment Partners Holdings N.V. Acquires 484,805 Shares of Abbott Laboratories (ABT)” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this report can be viewed at http://www.dailypolitical.com/2017/02/17/nn-investment-partners-holdings-n-v-acquires-484805-shares-of-abbott-laboratories-abt.html.
Several equities analysts recently weighed in on the stock. Jefferies Group LLC restated a “buy” rating and issued a $51.00 price objective on shares of Abbott Laboratories in a report on Friday. TheStreet lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 2nd. Royal Bank Of Canada cut their price objective on shares of Abbott Laboratories from $48.00 to $46.00 and set an “outperform” rating on the stock in a report on Thursday, January 26th. Zacks Investment Research lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, January 11th. Finally, RBC Capital Markets cut their price objective on shares of Abbott Laboratories from $48.00 to $46.00 and set an “outperform” rating on the stock in a report on Thursday, January 26th. Five equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $47.38.
In related news, insider Brian J. Blaser purchased 15,580 shares of the firm’s stock in a transaction that occurred on Tuesday, December 20th. The shares were bought at an average cost of $38.45 per share, with a total value of $599,051.00. Following the acquisition, the insider now owns 129,782 shares of the company’s stock, valued at approximately $4,990,117.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Heather L. Mason sold 35,700 shares of Abbott Laboratories stock in a transaction that occurred on Tuesday, January 31st. The shares were sold at an average price of $40.77, for a total transaction of $1,455,489.00. Following the sale, the insider now directly owns 100,189 shares in the company, valued at $4,084,705.53. The disclosure for this sale can be found here. Insiders own 0.26% of the company’s stock.
About Abbott Laboratories
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products.
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.